Notice regarding the Conclusion of an Agreement Concerning Manufacturing License with FUSO Pharmaceutical Industries, Ltd.
Published by
3-D Matrix
on
3-D Matrix, Ltd. (headquarters: Chiyoda-ku, Tokyo; President and Representative Director: Jun Okada; “the Company”) is pleased to announce the conclusion of a manufacturing license agreement (“the Agreement”) with FUSO Pharmaceutical Industries, Ltd. (“FUSO Pharmaceutical Industries”).
- Overview and background of the Agreement
On May 23, 2011, the Company concluded a manufacturing agreement with FUSO Pharmaceutical Industries concerning absorbable local hemostatic material that uses self-assembling peptides (“the Product”), and this manufacturing agreement was terminated on July 10, 2020, but, on December 21, 2020, the two companies agreed to continue manufacturing the necessary volume even after termination until the Company switched to a new contract manufacturer. After that, the Company discussed the possibility of continuing with manufacturing in the medium and long term with FUSO Pharmaceutical Industries, and, as a result, the Company concluded the Agreement, which concerns ongoing manufacturing, with FUSO Pharmaceutical Industries today. Based on the Agreement, the Company will subcontract the manufacturing of the Product to FUSO Pharmaceutical Industries.
Note that the Agreement will not result in any additional expenses. The plan is to appropriate subcontracting expenses (the cost of sales) according to future sales.
- Future outlook
As was disclosed on December 16, 2021, the Company has also concluded a manufacturing and service agreement with Pharmpur GmbH in Europe, where manufacturing has started, but the Company believes that—by also taking advantage of the manufacturing bases of FUSO Pharmaceutical Industries, which boasts an extensive track record of manufacturing the Product—it will be possible to more stably supply the Product, which will enable the Company to expand its business and contribute more effectively to the market. In the medium and long term, the Company will also strive to further scale up its production in order to reduce manufacturing costs.
Conclusion of the Agreement causes immaterial impact on the financial results for the current full fiscal year. If any other matters requiring disclosure arise, you will be promptly notified.
■ Overview of FUSO Pharmaceutical Industries
|
Trade Name |
Fuso Pharmaceutical Industries, Ltd. |
|
Location of Headquarters |
1-7-10 Doshomachi, Chuo-ku, Osaka-shi |
|
Date of Establishment |
March 25, 1937 |
|
Amount of Capital |
¥10,758 million |
|
Fiscal Year End |
March |
|
Number of Employees |
1,344 (as of March 31, 2022) |
|
Stock Listing |
Tokyo Stock Exchange Prime Market (securities code: 4538) |
■ Main content of the agreement termination notice dated July 10, 2020
- Termination of the Product manufacturing license agreement originally concluded with FUSO Pharmaceutical Industries on May 23, 2011
■ Main content of the agreement dated December 21, 2020
- Confirmation of the termination of both the exclusive Product distribution license agreement concluded with FUSO Pharmaceutical Industries on July 17, 2009, and the manufacturing license agreement concluded on May 23, 2011, as a result of the termination notice dated July 10, 2020
- Intention to manufacture the Product volume assumed to be necessary until the switch is made to a new contract manufacturer
Read the full article here.